Rocket Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 221.86 million compared to USD 169.07 million a year ago. Basic loss per share from continuing operations was USD 3.26 compared to USD 2.67 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.4 USD | -1.10% | +0.30% | -21.92% |
May. 10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
May. 10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.92% | 2.12B | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.38% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022